ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2021-003144
Abstract: Background Uterine serous carcinoma is a distinct histologic subtype of endometrial cancer with an aggressive phenotype, poor prognosis, and limited therapeutic options. A previous proof-of-concept phase II trial of the Wee1 inhibitor adavosertib in uterine… read more here.
Keywords: persistent uterine; uterine serous; women recurrent; recurrent persistent ... See more keywords